Leap Therapeutics, Inc. (NASDAQ: LPTX), relating to its proposed purchase of Flame Biosciences, Inc. Under the terms of the agreement, LPTX will issue shares of common stock and Series X non-voting convertible preferred stock to Flame shareholders, with each Series X share convert to 1000 shares of common stock upon approval of the transaction.